The Palvella Therapeutics, Inc. (Nasdaq: PVLA) SEC filings page on Stock Titan provides access to the company’s official disclosures as a clinical-stage biopharmaceutical issuer. Palvella’s filings describe a business focused on developing investigational topical therapies for serious, rare skin diseases and vascular malformations with no FDA-approved therapies, built around its patented QTORIN™ platform.
Through documents such as Form 8-K current reports, investors can review how Palvella communicates material events, including topline results from the Phase 2 TOIVA trial of QTORIN™ rapamycin for cutaneous venous malformations, updates on the Phase 3 SELVA trial in microcystic lymphatic malformations, and announcements of new product candidates like QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis. Other 8-K filings furnish earnings press releases, corporate presentations, and information about conference calls related to quarterly financial results and corporate updates.
These filings also confirm key structural details, such as Palvella’s incorporation in Nevada, its listing of common stock on The Nasdaq Capital Market under the symbol PVLA, and its description as a clinical-stage company. Regulation FD disclosures provide slide decks and presentations that elaborate on the company’s pipeline, regulatory designations, and development plans, while results-of-operations filings supply context on research and development spending and general and administrative costs associated with advancing QTORIN™ programs.
On Stock Titan, users can combine real-time updates from EDGAR with AI-assisted views of Palvella’s filings to more quickly understand the significance of new 8-Ks and related exhibits. This includes identifying which filings discuss clinical data, regulatory interactions, or financial performance, and how those disclosures relate to the company’s investigational product candidates, all while recognizing that QTORIN™ rapamycin and QTORIN™ pitavastatin remain unapproved therapies.
Palvella Therapeutics, Inc. reported a net loss of $15.8 million for the three months ended March 31, 2026, compared with $8.2 million a year earlier, as it increased investment in late-stage rare dermatology programs. Research and development expenses nearly doubled to $9.3 million, and general and administrative costs rose to $5.5 million.
The company significantly strengthened its balance sheet through a February 2026 equity financing, issuing 1,840,000 shares and lifting total cash and cash equivalents to $206.4 million, plus $55.5 million of short-term U.S. Treasury investments. Total assets were $263.8 million and stockholders’ equity was $232.3 million. Management expects existing cash resources to fund operations for at least one year while advancing QTORIN rapamycin and QTORIN pitavastatin through clinical development.
Palvella Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 10, 2026, including an amendment to the 2024 Equity Incentive Plan to add 750,000 shares for future awards. Investors will also elect three Class III directors, ratify Ernst & Young LLP as auditor, and cast advisory votes on executive pay and how often to hold future say‑on‑pay votes. The board, which has seven members and six independents with an independent chair, recommends voting “FOR” all six proposals, including a potential adjournment if support for the equity plan is insufficient.
Palvella Therapeutics, Inc. Chief Operating Officer Kathleen Goin exercised stock options and sold shares in pre-planned trades. On April 15, 2026, she exercised options for 2,154 shares of common stock at $7.14 per share and 2,148 shares at $9.08 per share, acquiring a total of 4,302 shares.
That same day, she executed open-market sales totaling 4,302 shares of common stock in multiple transactions, at weighted average prices including $125.9647, $127.1254, $128.2349, $129.1692, and $130.33 per share, with underlying trade ranges from $125.53 to $129.70 as disclosed. The filing states these transactions were carried out under a Rule 10b5-1 trading plan adopted on August 19, 2025 during an open trading window. After these transactions, the report shows 0 shares of common stock held directly by Goin, and no remaining option positions are listed.
Palvella Therapeutics director John Doux received a grant of stock options covering 6,000 shares of Common Stock. The options were awarded at an exercise price of $129.00 per share and expire on April 13, 2036.
The grant vests in 36 equal monthly installments, conditioned on Doux’s continued service with the company on each vesting date. After this award, he holds 6,000 stock options directly under this grant.
PALVELLA THERAPEUTICS, INC. director John Doux filed an initial ownership report showing a stock option holding. The filing lists a fully vested stock option to acquire 10,364 shares of common stock at an exercise price of $7.14 per share, expiring on February 4, 2030.
Palvella Therapeutics (PVLA) submitted a Form 144 notice reporting proposed sales of Common Stock tied to a stock option exercise with an intended sale date of 04/15/2026. The filing lists recent open-market disposals in the prior three months of $419,983.18, $341,563.74, and $507,611.05, and identifies Piper Sandler & Co. as the broker.
Palvella Therapeutics, Inc. expanded its Board of Directors from six to seven members and appointed John Doux, M.D. as a Class III director, with his term ending at the 2026 Annual Meeting of Stockholders. The Board determined that he is independent under applicable Nasdaq listing rules.
Dr. Doux is a board-certified dermatologist and long-time healthcare investment analyst at Palo Alto Investors LP, with prior board experience at Palvella and several biotechnology companies. Under the company’s Non-Employee Director Compensation Policy, he received an option to purchase 6,000 shares of common stock, vesting in equal monthly installments over 36 months, subject to continued service.
Palvella Therapeutics filed an 8‑K to share an updated corporate presentation highlighting progress in its rare disease pipeline. The lead candidate, QTORIN™ 3.9% rapamycin gel for microcystic lymphatic malformations, delivered highly statistically significant Phase 3 SELVA results, with a mean +2.13 improvement on the mLM‑IGA primary endpoint and p<0.001 across primary, key secondary, and all four secondary endpoints. The program has Breakthrough, Fast Track, and Orphan Designations, with a U.S. NDA submission targeted for the second half of 2026 and potential FDA approval in the first half of 2027. Palvella also reported positive Phase 2 data in cutaneous venous malformations, Fast Track designation and planned Phase 2 initiation for angiokeratomas, and a QTORIN™ pitavastatin program for DSAP. Following an oversubscribed February 2026 equity financing, the company cites approximately $274 million in pro forma cash to support regulatory filings, potential U.S. launch, and multiple Phase 2 readouts.
PALVELLA THERAPEUTICS, INC. director George M. Jenkins made an open-market purchase of common stock. On March 30, 2026, he bought 445 shares of Palvella Therapeutics common stock at $112.30 per share. Following this trade, he directly holds 187,616 shares and has an additional 13,516 shares reported as indirectly held through the Eagles Mere Air Museum Foundation.